Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants
- PMID: 20195905
- DOI: 10.1007/s11136-010-9620-x
Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants
Abstract
Background and aims: Valid instruments are needed to assess important patient-reported outcomes (PROs) in erosive esophagitis (EE).
Methods: Data from 4,092 patients in clinical trials to determine efficacy of dexlansoprazole MR to heal EE and maintain healed EE were used to assess the psychometric properties of the Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) and the PAGI-Symptoms Severity Index (PAGI-SYM). A daily diary, gastroesophageal reflux disease (GERD) Symptoms Investigator Assessment and endoscopy results were also used in this study.
Results: PAGI-QOL and PAGI-SYM subscales and total score internal consistency reliability estimates for both studies were acceptable (Cronbach's alpha coefficient = 0.81-0.97). Most subscale and total scores yielded moderate-to-strong correlations with other measures reflecting signs and symptoms of EE. Some subscales were able to detect differences >1 standard error of measurement (SEM) in change scores among patients with improved heartburn frequency compared to those with stable/worsening heartburn frequency in the healing study. Those with relapsed EE demonstrated differences >1 SEM in some PAGI-QOL and PAGI-SYM subscale or total scores compared to patients who maintained their healing status.
Conclusion: The findings of this study support the consideration of the PAGI-QOL and PAGI-SYM in future clinical trials and in the general EE population.
Similar articles
-
Dexlansoprazole for the treatment of esophagitis and GERD.Drugs Today (Barc). 2010 Feb;46(2):75-80. doi: 10.1358/dot.2010.46.2.1437714. Drugs Today (Barc). 2010. PMID: 20393635
-
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.Clin Gastroenterol Hepatol. 2012 Mar;10(3):247-53. doi: 10.1016/j.cgh.2011.11.021. Epub 2011 Dec 7. Clin Gastroenterol Hepatol. 2012. PMID: 22155561 Clinical Trial.
-
Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders.Qual Life Res. 2004 Dec;13(10):1737-49. doi: 10.1007/s11136-004-9567-x. Qual Life Res. 2004. PMID: 15651544
-
Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.Drugs. 2010 Aug 20;70(12):1593-601. doi: 10.2165/11295960-000000000-00000. Drugs. 2010. PMID: 20687622 Review.
-
Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.Ann Pharmacother. 2010 May;44(5):871-7. doi: 10.1345/aph.1M685. Epub 2010 Apr 6. Ann Pharmacother. 2010. PMID: 20371754 Review.
Cited by
-
Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BAD-BURN) in World Trade Center exposed firefighters: a case-control observational study protocol.BMC Gastroenterol. 2024 Aug 9;24(1):255. doi: 10.1186/s12876-024-03294-9. BMC Gastroenterol. 2024. PMID: 39123126 Free PMC article.
-
Factors that contribute to the impairment of quality of life in gastroparesis.Neurogastroenterol Motil. 2021 Aug;33(8):e14087. doi: 10.1111/nmo.14087. Epub 2021 Jan 25. Neurogastroenterol Motil. 2021. PMID: 33493377 Free PMC article.
-
Diet quality in cystic fibrosis - associations with patient reported outcome measures and enablers and barriers to eating a healthy diet: A protocol paper for a mixed methods study.HRB Open Res. 2022 May 5;5:33. doi: 10.12688/hrbopenres.13533.1. eCollection 2022. HRB Open Res. 2022. PMID: 36091185 Free PMC article.
-
Duodenal rather than antral motility contractile parameters correlate with symptom severity in gastroparesis patients.Neurogastroenterol Motil. 2015 Mar;27(3):339-46. doi: 10.1111/nmo.12496. Epub 2014 Dec 17. Neurogastroenterol Motil. 2015. PMID: 25521513 Free PMC article.
-
Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment.Neurogastroenterol Motil. 2015 Feb;27(2):258-68. doi: 10.1111/nmo.12484. Epub 2014 Dec 21. Neurogastroenterol Motil. 2015. PMID: 25530111 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous